Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse and / or Refractory Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT06961669
What this trial is testing

Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma

Who this might be right for
Lymphoblastic LeukemiaRelapsed or Refractory Multiple Myeloma (RRMM)
Anhui Provincial Hospital 18
Early research (Phase 1)Active Not RecruitingNCT05259839
What this trial is testing

Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
AbbVie 283
Early research (Phase 1)Active Not RecruitingNCT05286229
What this trial is testing

Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan

Who this might be right for
Relapsed/Refractory Multiple Myeloma
AbbVie 8
Testing effectiveness (Phase 2)UnknownNCT05719701
What this trial is testing

Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma
Beijing InnoCare Pharma Tech Co., Ltd. 80
Testing effectiveness (Phase 2)Looking for participantsNCT05714839
What this trial is testing

Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 123
Testing effectiveness (Phase 2)Ended earlyNCT00765102
What this trial is testing

Trial of Romidepsin and Bortezomib for Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 32
Not applicableStudy completedNCT03188536
What this trial is testing

Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study)

Who this might be right for
Multiple Myeloma
Takeda 282
Not applicableStudy completedNCT04458831
What this trial is testing

A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Plasma Cell Myeloma
Sanofi 583
Early research (Phase 1)UnknownNCT00821301
What this trial is testing

Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Immune Control 30
Early research (Phase 1)Ended earlyNCT04702425
What this trial is testing

VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

Who this might be right for
Non-Hodgkin Lymphoma (NHL)Acute Myeloid Leukemia (AML)Multiple Myeloma (MM)
Novartis Pharmaceuticals 37
Testing effectiveness (Phase 2)UnknownNCT03090659
What this trial is testing

LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma

Who this might be right for
Refractory or Relapsed Multiple Myeloma
Nanjing Legend Biotech Co. 100
Early research (Phase 1)Looking for participantsNCT06121843
What this trial is testing

Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 187
Large-scale testing (Phase 3)Active Not RecruitingNCT04975997
What this trial is testing

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
Celgene 939
Early research (Phase 1)Looking for participantsNCT05652335
What this trial is testing

JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Who this might be right for
Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC 180
Testing effectiveness (Phase 2)Ended earlyNCT01118013
What this trial is testing

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

Who this might be right for
LeukemiaLymphomaLymphoproliferative Disorder+3 more
Alliance for Clinical Trials in Oncology 6
Early research (Phase 1)Study completedNCT01556438
What this trial is testing

Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Eli Lilly and Company 16
Not applicableNot Yet RecruitingNCT07015021
What this trial is testing

The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients

Who this might be right for
Multiple MyelomaCarfilzomibDaratumumab+1 more
The First Affiliated Hospital of Soochow University 72
Large-scale testing (Phase 3)Study completedNCT00063726
What this trial is testing

PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039

Who this might be right for
Multiple Myeloma
Millennium Pharmaceuticals, Inc. 600
Early research (Phase 1)Not Yet RecruitingNCT07725406
What this trial is testing

Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

Who this might be right for
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed or Refractory Multiple Myeloma (MM)
Weill Medical College of Cornell University 32
Not applicableUnknownNCT05297240
What this trial is testing

Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.

Who this might be right for
RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
PETHEMA Foundation 170
Next Page